ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Jul 27, 2022 07:00AM
ORTHO REGENERATIVE TECHNOLOGIES INITIATES PATIENTS RECRUITMENT FOR ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Jun 13, 2022 08:44AM
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES $500,000 AXELYS GRANT TO ADVANCE ORTHO-M DEVELOPMENT FOR MENISCUS REPAIR May 26, 2022 07:00AM
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT FOR ORTHO-R SOFT TISSUE REPAIR PLATFORM May 4, 2022 07:00AM
ORTHO REGENERATIVE TECHNOLOGIES TO PARTICIPATE IN THE 2022 VIRTUAL GROWTH CONFERENCE PRESENTED BY MAXIM GROUP LLC AND HOSTED BY M-VEST Mar 24, 2022 07:00AM


Mar 15, 2022 07:00AM ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
Feb 11, 2022 08:35AM ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES $3 MILLION NON-BROKERED PRIVATE PLACEMENT OF UNITS
Feb 7, 2022 07:00AM ORTHO REGENERATIVE TECHNOLOGIES ENTERS INTO A MATERIAL TRANSFER AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ORTHO-R ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL
Dec 13, 2021 10:34AM ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES U.S. IND CLINICAL HOLD LIFTED BY THE FDA & CLEARANCE TO PROCEED WITH U.S. CLINICAL TRIAL.
Oct 6, 2021 01:39PM Ortho Regenerative Technologies Announces Successful Type A Meeting With U.S. FDA on CMC Elements For Which More Information Was Required to Clear IND Clinical Hold
Aug 20, 2021 08:41AM Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application
Jul 20, 2021 07:00AM Ortho Regenerative Technologies Submits Formal Response to U.S. FDA Clinical Hold
Jun 15, 2021 07:00AM Ortho Regenerative Technologies Appoints Two New Members to its Board of Directors
Jun 4, 2021 07:00AM Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA
Apr 6, 2021 07:15AM Ortho Regenerative Technologies Announces Submission of Investigational New Drug Application for ORTHO-R
Mar 31, 2021 07:00AM Ortho Regenerative Technologies Secures DTC Eligibility for the Trading of Its Shares On the US OTCQB Market
Mar 2, 2021 07:00AM Ortho Regenerative Technologies Well-positioned for Next Phase of Development
Feb 24, 2021 07:00AM Ortho Regenerative Technologies Adds Patrick O'Donnell to Board of Directors
Feb 10, 2021 07:00AM Ortho Regenerative Technologies launches AGORACOM platform for online investors outreach
Feb 4, 2021 07:00AM Ortho Regenerative Technologies Retains Westwicke ICR as Investor Relations Advisors for the U.S.
Jan 5, 2021 07:00AM Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.
Dec 3, 2020 08:44AM Ortho Regenerative Technologies Completes Non-Brokered $3.0 Million Private Placement
Oct 28, 2020 07:00AM Ortho Regenerative Technologies Begins Trading on the OTCQB U.S. Market
Oct 19, 2020 07:00AM Ortho Regenerative Technologies Announces the Nomination of its New Vice-president Clinical and Medical Affairs
Sep 25, 2020 07:00AM Ortho Regenerative Technologies Reports its Second Quarter 2021 Results
Aug 24, 2020 07:00AM Ortho Regenerative Technologies Closes Non-Brokered $2.5 Million Private Placement
Aug 6, 2020 07:05AM Ortho Regenerative Technologies Announces FDA Regulatory Designation and Jurisdictional Assignment for Ortho-R
Jul 28, 2020 07:00AM Ortho Regenerative Technologies Releases New Positive Histology Results From Pivotal Preclinical GLP Rotator Cuff Tear Repair Efficacy Study in Large-Animal Model